Comparative Pharmacology
Head-to-head clinical analysis: RUBRACA versus ZEJULA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RUBRACA versus ZEJULA.
RUBRACA vs ZEJULA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. It inhibits PARP enzymatic activity and traps PARP-DNA complexes, leading to DNA damage, apoptosis, and cell death in tumor cells with homologous recombination repair deficiencies (e.g., BRCA mutations).
Poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. Inhibits PARP catalytic activity and traps PARP-DNA complexes, leading to accumulation of DNA damage and apoptosis in BRCA-deficient tumor cells.
600 mg orally twice daily, with or without food, total daily dose 1200 mg.
300 mg orally once daily with or without food.
None Documented
None Documented
The terminal elimination half-life (t1/2) is approximately 17 hours, supporting twice-daily dosing (600 mg twice daily) to maintain steady-state concentrations within the therapeutic window.
36 ± 13 hours; supports twice-daily dosing; in moderate hepatic impairment (Child-Pugh B), t1/2 prolonged to 58 hours.
Approximately 44% of the administered dose is excreted in feces (with 38% as unchanged drug) and 28% in urine (with 7% as unchanged drug). The remainder is recovered as metabolites in feces and urine, with biliary excretion being a minor route.
Renal: 70.9% (11.1% unchanged); fecal: 15.5%; metabolism via carboxylesterases (CES1/CES2) and renal excretion of metabolites.
Category C
Category C
PARP Inhibitor
PARP Inhibitor